| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/ANA.410250308 |
| P698 | PubMed publication ID | 2524992 |
| P2093 | author name string | Miller C | |
| Behr J | |||
| Goldblatt D | |||
| Kennedy J | |||
| Shoulson I | |||
| Rubin A | |||
| Bamford K | |||
| Caine E | |||
| Oakes D | |||
| Odoroff C | |||
| P2860 | cites work | Non-cholinergic synaptic excitation in neostriatum: pharmacological evidence for mediation by a glutamate-like transmitter | Q35887348 |
| Two types of gamma-aminobutyric acid receptor on embryonic sensory neurones | Q39931499 | ||
| Huntington's disease in Venezuela: neurologic features and functional decline | Q45297315 | ||
| Normal caudate glucose metabolism in persons at risk for Huntington's disease | Q45298212 | ||
| Huntington disease: functional capacities in patients treated with neuroleptic and antidepressant drugs | Q45303724 | ||
| Multiple sclerosis in Iceland: 1. Evidence of a postwar epidemic | Q50590075 | ||
| P433 | issue | 3 | |
| P921 | main subject | Huntington's disease | Q190564 |
| P304 | page(s) | 252-259 | |
| P577 | publication date | 1989-03-01 | |
| P1433 | published in | Annals of Neurology | Q564414 |
| P1476 | title | A controlled clinical trial of baclofen as protective therapy in early Huntington's disease | |
| P478 | volume | 25 |
| Q35753388 | A review of the treatment options for Huntington's disease |
| Q38624994 | Advancing pharmacotherapy for treating Huntington's disease: a review of the existing literature |
| Q30660685 | An overview of psychiatric symptoms in Huntington's disease |
| Q38248687 | Animal models of Huntington's disease for translation to the clinic: best practices |
| Q45290173 | Antidopaminergic Medication is Associated with More Rapidly Progressive Huntington's Disease |
| Q45295617 | Differential responses of extracellular GABA to intrastriatal perfusions of 3-nitropropionic acid and quinolinic acid in the rat |
| Q38792714 | Discovery of Therapeutic Approaches for Polyglutamine Diseases: A Summary of Recent Efforts |
| Q37488273 | Emerging drug therapies in Huntington's disease |
| Q41628677 | Huntington Disease and the Related Disorder, Dentatorubral-Pallidoluysian Atrophy (DRPLA) |
| Q34247413 | Huntington's Disease: Advocacy Driving Science |
| Q33921449 | Huntington's disease: pathogenesis, diagnosis and treatment |
| Q40612866 | Huntington's disease: update and review of neuropsychiatric aspects |
| Q45305483 | Motor, cognitive, and functional declines contribute to a single progressive factor in early HD. |
| Q38163877 | Neuroprotective effects of psychotropic drugs in Huntington's disease |
| Q41258822 | Pharmacological options for the management of dyskinesias |
| Q45297193 | Prospectives for cell and gene therapy in Huntington's disease |
| Q45288751 | Psychopathological changes preceding motor symptoms in Huntington's disease: a report on four cases |
| Q45300446 | Rate of caudate atrophy in presymptomatic and symptomatic stages of Huntington's disease |
| Q58574520 | Rating Scales and Performance-based Measures for Assessment of Functional Ability in Huntington's Disease: Critique and Recommendations |
| Q92978549 | Resting-state connectivity stratifies premanifest Huntington's disease by longitudinal cognitive decline rate |
| Q37131233 | Symptomatic treatment of Huntington disease |
| Q35597607 | The Current Status of Neural Grafting in the Treatment of Huntington's Disease. A Review |
| Q36684263 | The corticostriatal pathway in Huntington's disease |
| Q38202178 | The most appropriate primary outcomes to design clinical trials on Huntington's disease: meta-analyses of cohort studies and randomized placebo-controlled trials |
| Q33790829 | Therapeutic Strategies in Huntington's Disease |
| Q24239973 | Therapeutic interventions for disease progression in Huntington's disease |
| Q34205521 | Therapeutic opportunities in polyglutamine disease |
| Q36277195 | Therapeutics development for triplet repeat expansion diseases |
| Q53716390 | Therapy development in Huntington disease: From current strategies to emerging opportunities. |
| Q35479486 | Topography of cerebral atrophy in early Huntington's disease: a voxel based morphometric MRI study. |
| Q33596210 | Trinucleotide repeat length and progression of illness in Huntington's disease |
Search more.